Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors (STAR-T-NET)
2021-002218-15Phase 3Active
- Sponsor
- Region Skåne
- Start
- Oct 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177-edotreotide in apudoma (NET) (2 arms), sponsored by Region Skåne. Primary endpoint: Progression-free survival. Started Oct 2021; status: active.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2021-002218-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002218-15.